Drug Profile
Research programme: biodefence therapeutics - Evolva/Summit
Alternative Names: Biodefense therapeutics - Evolva/Summit; EV 009; EV-009-4400; SMT-15000Latest Information Update: 20 Sep 2010
Price :
$50
*
At a glance
- Originator Summit plc
- Developer Evolva Holding SA; Summit plc
- Class Imino sugars; Small molecules
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections; Viral infections
Most Recent Events
- 07 Sep 2010 Preclinical development in Viral infections and Bacterial infections due to biowarfare is continuing in the UK (PO)